Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients

Pediatric Reports

Volumn 4, Issue 1, 2012, Pages

  Cugno, Chiara ^a   Cesaro, Simone ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Candida spp. Sepsis; Candidemia

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; DEOXYCHOLIC ACID; FLUCONAZOLE; MICAFUNGIN; VANCOMYCIN; VORICONAZOLE;

AGE DISTRIBUTION; APLASTIC ANEMIA; BLOOD CULTURE; BLOODSTREAM INFECTION; BONE MARROW TRANSPLANTATION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; CENTRAL VENOUS CATHETER; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE ASSOCIATION; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HIGH RISK PATIENT; INCIDENCE; INFECTION RISK; INTENSIVE CARE UNIT; MOLECULAR EPIDEMIOLOGY; MORBIDITY; MORTALITY; PEDIATRICS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SPECIES DIFFERENTIATION;

EID: 84870557290     PISSN: None     EISSN: 20367503     Source Type: Journal    
DOI: 10.4081/pr.2012.e9     Document Type: Review

References (34)

1. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
3. Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003;22: 686-916.
4. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population based active surveillance. Clin Infect Dis 1999;29: 1164-70.
5. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population based active surveillance program. J Clin Microbiol 2004;42:1519-27.
6. Manno G, Scaramuccia A, Rossi R, et al. Trends in antifungal use and species distribution among Candida isolates in a large paediatric hospital. Int J Antimicrob Agents 2004;24:627-8.
7. Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003;167:695-701.
8. Kaya Z, Gursel T, Kocak U, et al. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer 2009;52:470-5.
9. Rosen GP, Nielsen K, Glenn S, et al. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 2005;27:135-40.
10. Castagnola E, Cesaro S, Giacchino M, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J 2006;25:634-9.
11. Mor M, Gilad G, Kornreich L, et al. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011;56:1092-7.
12. MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a children's hospital. Clin Infect Dis 1998;26:642-5.
13. Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005;36:621-9.
14. Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010;51:e38-45.
15. Blyth CC, Chen SC, Slavin MA, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009;123:1360-8.
16. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009;48:1695-703.
17. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634- 43.
18. Mikulska M, Calandra T, Sanguinetti M, et al. Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010;14:R222.
19. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31.
20. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42.
21. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331:1325-30.
22. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
23. VandenBussche HL, Van Loo DA. A clinical review of echinocandins in pediatric patients. Ann Pharmacother 2010;44:166- 77.
24. Ikeda F, Saika T, Sato Y, et al. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med Mycol 2009;47:145- 8.
25. Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005;25:770-7.
26. Merlin E, Galambrun C, Ribaud P, et al. Efficacy and safety of caspofungin therapy in children with invasive fungal infections. Pediatr Infect Dis J 2006;25:1186-8.
27. Groll AH, Attarbasc A, Schuster FR, et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother 2006;57:527-35.
28. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised doubleblind trial. Lancet 2007;369:1519-27.
29. Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for the treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93.
30. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008;27:820-6.
31. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-61.
32. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356: 2472-82.
33. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35.
34. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant 2011;46:709-18.